[1] Shultz L D, Ishikawa F, Greiner D L. Humanized mice in translational biomedical research[J]. Nature Reviews Immunology, 2007, 7(2): 118-130.
[2] Isaacson J H, Cattanach B M. Mouse News Letter[J]. 1962.
[3] Fulop G M, Phillips R A. The scid mutation in mice causes a general defect in DNA repair[J]. Nature, 1990, 347(6292): 479-482.
[4] Malynn B A, Blackwell T K, Fulop G M, et al. The< i> scid</i> defect affects the final step of the immunoglobulin VDJ recombinase mechanism[J]. Cell, 1988, 54(4): 453-460.
[5] Berney T, Molano R D, Pileggi A, et al. Patterns of Engraftment in Different Strains of Immunodeficient Mice Reconstituted With Human Peripheral Blood Lymphocytes1[J]. Transplantation, 2001, 72(1): 133-140.
[6] Roychowdhury S, Blaser B W, Freud A G, et al. IL-15 but not IL-2 rapidly induces lethal xenogeneic graft-versus-host disease[J]. Blood, 2005, 106(7): 2433-2435.
[7] Hesselton R A M, Greiner D L, Mordes J P, et al. High levels of human peripheral blood mononuclear cell engraftment and enhanced susceptibility to human immunodeficiency virus type 1 infection in NOD/LtSz-scid/scid mice[J]. Journal of Infectious Diseases, 1995, 172(4): 974-982.
[8] Lepus C M, Gibson T F, Gerber S A, et al. Comparison of human fetal liver, umbilical cord blood, and adult blood hematopoietic stem cell engraftment in NOD-< i> scid</i>/γc< sup>-/-</sup>, Balb/c-< i> Rag1</i>< sup>-/-</sup> γc< sup>-/-</sup>, and CB-17-< i> scid</i>/bg immunodeficient mice[J]. Human immunology, 2009, 70(10): 790-802.
[9] Shultz L D, Schweitzer P A, Christianson S W, et al. Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice[J]. The Journal of Immunology, 1995, 154(1): 180-191.
[10] Prochazka M, Gaskins H R, Shultz L D, et al. The nonobese diabetic scid mouse: model for spontaneous thymomagenesis associated with immunodeficiency[J]. Proceedings of the National Academy of Sciences, 1992, 89(8): 3290-3294.
[11] Shinkai Y. RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V (D) J rearrangement[J]. Cell, 1992, 68(5): 855-867.
[12] Mombaerts P, Iacomini J, Johnson R S, et al. RAG-1-deficient mice have no mature B and T lymphocytes[J]. Cell, 1992, 68(5): 869-877.
[13] Oettinger M A, Schatz D G, Gorka C, et al. RAG-1 and RAG-2, adjacent genes that synergistically activate V (D) J recombination[J]. Science, 1990, 248(4962): 1517-1523.
[14] Gellert M. V (D) J Recombination: RAG Proteins, Repair Factors, and Regulation[J]. Annual review of biochemistry, 2002, 71(1): 101-132.
[15] Shultz L D, Lang P A, Christianson S W, et al. NOD/LtSz-Rag1null mice: an immunodeficient and radioresistant model for engraftment of human hematolymphoid cells, HIV infection, and adoptive transfer of NOD mouse diabetogenic T cells[J]. The Journal of Immunology, 2000, 164(5): 2496-2507.
[16] Ito M, Hiramatsu H, Kobayashi K, et al. NOD/SCID/γ mouse: an excellent recipient mouse model for engraftment of human cells[J]. Blood, 2002, 100(9): 3175-3182.
[17] Rochman Y, Spolski R, Leonard W J. New insights into the regulation of T cells by γc family cytokines[J]. Nature Reviews Immunology, 2009, 9(7): 480-490.
[18] Shultz L D, Lyons B L, Burzenski L M, et al. Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2Rγnull mice engrafted with mobilized human hemopoietic stem cells[J]. The Journal of Immunology, 2005, 174(10): 6477-6489.
[19] McDermott SP, Eppert K, Lechman ER, et al. Comparison of human cord blood engraftment between immunocompromised mouse strains[J]. Blood, 2010, 116(2): 193-200.
[20] Pearson T, Shultz LD, Miller D, et al. Non‐obese diabetic-recombination activating gene‐1 (NOD-Rag 1 null) interleukin (IL)‐2 receptor common gamma chain (IL 2 rγnull) null mice: a radioresistant model for human lymphohaematopoietic engraftment[J]. Clinical & Experimental Immunology, 2008, 154(2): 270-284.
[21] Brehm MA, Cuthbert A, Yang C, et al. Parameters for establishing humanized mouse models to study human immunity: Analysis of human hematopoietic stem cell engraftment in three immunodeficient strains of mice bearing the< i> IL2r</i> γ< sup> null</sup> mutation[J]. Clinical Immunology, 2010, 135(1): 84-98.
[22] Büchner SM, Sliva K, Bonig H, et al. Delayed onset of graft‐versus‐host disease in immunodeficent human leucocyte antigen‐DQ8 transgenic, murine major histocompatibility complex class II‐deficient mice repopulated by human peripheral blood mononuclear cells[J]. Clinical & Experimental Immunology, 2013, 173(2): 355-364.
[23] Suzuki M, Takahashi T, Katano I, et al. Induction of human humoral immune responses in a novel HLA-DR-expressing transgenic NOD/Shi-scid/γcnull mouse[J]. International immunology, 2012, 24(4): 243-252.
[24] Danner R, Chaudhari SN, Rosenberger J, et al. Expression of HLA class II molecules in humanized NOD. Rag1KO. IL2RgcKO mice is critical for development and function of human T and B cells[J]. PLoS One, 2011, 6(5): e19826.
[25] Puliaev RA, Puliaeva IA, Ryan AE, et al. The parent-into-F1 model of graft-vs-host disease as a model of in vivo T cell function and immunomodulation[J]. Current medicinal chemistry. Immunology, endocrine & metabolic agents, 2005, 5(6): 575.
[26] Via CS. Implications of the parent-into-F1 model for human lupus pathogenesis: roles for cytotoxic T lymphocytes and viral pathogens[J]. Current opinion in rheumatology, 2010, 22(5): 493.
[27] Hoffmann-Fezer G, Gall C, Zengerle U, et al. Immunohistology and immunocytology of human T-cell chimerism and graft-versus-host disease in SCID mice[J]. Blood, 1993, 81(12): 3440-3448.
[28] van Rijn RS, Simonetti ER, Hagenbeek A, et al. A new xenograft model for graft-versus-host disease by intravenous transfer of human peripheral blood mononuclear cells in RAG2-/-γc-/-double-mutant mice[J]. Blood, 2003, 102(7): 2522-2531.
[29] King MA, Covassin L, Brehm MA, et al. Human peripheral blood leucocyte non‐obese diabetic‐severe combined immunodeficiency interleukin‐2 receptor gamma chain gene mouse model of xenogeneic graft‐versus‐host‐like disease and the role of host major histocompatibility complex[J]. Clinical & Experimental Immunology, 2009, 157(1): 104-118.
[30] Ito R, Katano I, Kawai K, et al. Highly sensitive model for xenogenic GVHD using severe immunodeficient NOG mice[J]. Transplantation, 2009, 87(11): 1654-1658.
[31] Tary-Lehmann M, Saxon A, Lehmann P V. The human immune system in hu-PBL-SCID mice[J]. Immunology today, 1995, 16(11): 529-533.
[32] Ishikawa F, Yasukawa M, Lyons B, et al. Development of functional human blood and immune systems in NOD/SCID/IL2 receptor γ chain null mice[J]. Blood, 2005, 106(5): 1565-1573.
[33] Suzuki N, Yamazaki S, Yamaguchi T, et al. Generation of engraftable hematopoietic stem cells from induced pluripotent stem cells by way of teratoma formation[J]. Molecular Therapy, 2013,21（7）：1424-1431.
[34] Pearson T, Greiner D L, Shultz L D. Creation of “humanized” mice to study human immunity[J]. Current Protocols in Immunology, 2008,21（15）1-21. |
